Eventually the FDA has to begin removal of non-ADF opiods. Or leave non-ADF opiods for Clinical settings ONLY.
Nasrat said there has to be a few competitors for each opiod, each immediate or extended release delivery system. If the FDA does not do this everyone is wasting their time investing in ADF opiods.
Can't stop abuse if you don't take away what they are abusing.
Elite with SequestOx and Eaglet with Oxagio will have the IR ADF Oxy
Modality covered. What would an FDA mandate do to share price if 2-3 companies end up with 91 % of all new opiod RXs(IR opiods for acute pain)
The big question is When? 2017 or 2018?
Eventually first generation ADFs like OxyContin maybe removed and replaced by better products, this maybe a long time from now.
There is hope for more than just a couple $dollars a share.
Like a Couch says, A perfect storm is brewing !
Big Surprises are possible with Elite.
I expect ELI202 to be a generic PErcoset ADF(maybe not a great ADF but an ADF) one bead ER oxy/APAP which is resistant to snorting(nasal) abuse only. We may see FDA filing before SequestOx Approval?
Epic's new ER oxy will be removed from the market and replaced in a few years with Elites ER ADF oxycodone ELI-201.
Don't give up on ELI-216 ER 24 hour(once/day) ADF oxycodone.
I see a partnership developing with this one. SequestOx launch will give potential partners the confidence they need to jump on board.
Market Data 
Markets 
AI
